CoChat

Amyloid-beta uptake by blood monocytes is reduced with ageing and Alzheimer’s disease

Open access

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Abstract

Deficits in the clearance of amyloid β-protein (Aβ) play a pivotal role in the pathogenesis of sporadic Alzheimer’s disease (AD). The roles of blood monocytes in the development of AD remain unclear. In this study, we sought to investigate the alterations in the Aβ phagocytosis function of peripheral monocytes during ageing and in AD patients. A total of 104 cognitively normal participants aged 22–89 years, 24 AD patients, 25 age- and sex-matched cognitively normal (CN) subjects, 15 Parkinson’s disease patients (PD), and 15 age- and sex-matched CN subjects were recruited. The Aβ uptake by blood monocytes was measured and its alteration during ageing and in AD patients were investigated. Aβ 1-42 uptake by monocytes decreased during ageing and further decreased in AD but not in PD patients. Aβ 1-42 uptake by monocytes was associated with Aβ 1-42 levels in the blood. Among the Aβ uptake-related receptors and enzymes, the expression of Toll-like receptor 2 (TLR2) was reduced in monocytes from AD patients. Our findings suggest that monocytes regulate the blood levels of Aβ and might be involved in the development of AD. The recovery of the Aβ uptake function by blood monocytes represents a potential therapeutic strategy for AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41398-020-01113-9

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Imaging flow cytometry of Aβ1-42 uptake of monocyte subsets. A Single cells were selected from debris by gating on cells in focus, B followed by gating on the area and aspect ratio of the brightfield image. C Cells with high-intensity labelling of CD14 were chosen as monocytes. Monocytes were stained with APC-conjugated anti-CD14 mAb (red) and PE-conjugated anti-CD16 mAb (yellow), whereas FITC-conjugated Aβ1-42 is shown in green. Images of FITC-labelled Aβ1-42 uptake by the classic CD14+CD16− monocyte subset (D), intermediate CD14+CD16+ monocyte subset (E) and non-classical CD14dimCD16+ monocyte subset were collected (F). G, H For the measurement of Aβ1-42 uptake by monocyte subsets, monocytes were gated based on FSC-H and SSC-H. Three monocyte subsets, including classical monocyte subset CD14+CD16− (g1), intermediate monocyte subset CD14+CD16+ (g2) and non-classical monocyte subset CD14dimCD16+ (g3), were gated based on the expression of CD14 and CD16. I n = 44 per group, a paired t test, two sided. **p < 0.01. MONO monocytes, FSC-H forward scatter height, SSC-H side scatter height, Aβ amyloid-β protein.
Fig. 1 Imaging flow cytometry of Aβ1-42 uptake of monocyte subsets. A Single cells were selected from debris by gating on cells in focus, B followed by gating on the area and aspect ratio of the brightfield image. C Cells with high-intensity labelling of CD14 were chosen as monocytes. Monocytes were stained with APC-conjugated anti-CD14 mAb (red) and PE-conjugated anti-CD16 mAb (yellow), whereas FITC-conjugated Aβ1-42 is shown in green. Images of FITC-labelled Aβ1-42 uptake by the classic CD14+CD16− monocyte subset (D), intermediate CD14+CD16+ monocyte subset (E) and non-classical CD14dimCD16+ monocyte subset were collected (F). G, H For the measurement of Aβ1-42 uptake by monocyte subsets, monocytes were gated based on FSC-H and SSC-H. Three monocyte subsets, including classical monocyte subset CD14+CD16− (g1), intermediate monocyte subset CD14+CD16+ (g2) and non-classical monocyte subset CD14dimCD16+ (g3), were gated based on the expression of CD14 and CD16. I n = 44 per group, a paired t test, two sided. **p < 0.01. MONO monocytes, FSC-H forward scatter height, SSC-H side scatter height, Aβ amyloid-β protein.CC BY · PubMed Central
Fig. 2 Correlation and trajectory of Aβ1-42 uptake by monocyte subsets relative to age. Spearman correlation analysis was utilized to investigate the correlation between age and the uptake of Aβ1-42 by all monocytes (A), by the CD14+CD16− subset (B), by the CD14+CD16+ subset (C) and by the CD14dimCD16− subset (D). E The trajectory of Aβ1-42 uptake by total monocytes, CD14dimCD16+ and the CD14+CD16− subsets relative to age was modelled using Fit spline/Lowess (cubic) spline. n = 104. MONO monocytes, Aβ amyloid-β protein.
Fig. 2 Correlation and trajectory of Aβ1-42 uptake by monocyte subsets relative to age. Spearman correlation analysis was utilized to investigate the correlation between age and the uptake of Aβ1-42 by all monocytes (A), by the CD14+CD16− subset (B), by the CD14+CD16+ subset (C) and by the CD14dimCD16− subset (D). E The trajectory of Aβ1-42 uptake by total monocytes, CD14dimCD16+ and the CD14+CD16− subsets relative to age was modelled using Fit spline/Lowess (cubic) spline. n = 104. MONO monocytes, Aβ amyloid-β protein.CC BY · PubMed Central
Fig. 3 Association of monocyte Aβ1-42 uptake with plasma Aβ1-42 levels in CN subjects. Correlations between plasma Aβ1-42 and the uptake of Aβ1-42 by all monocytes (A), by the CD14+CD16− subset (B), by the CD14+CD16+ subset (C) and by the CD14dimCD16− subset (D). n = 25, covariate correlation analysis. MONO monocytes, Aβ amyloid-β protein.
Fig. 3 Association of monocyte Aβ1-42 uptake with plasma Aβ1-42 levels in CN subjects. Correlations between plasma Aβ1-42 and the uptake of Aβ1-42 by all monocytes (A), by the CD14+CD16− subset (B), by the CD14+CD16+ subset (C) and by the CD14dimCD16− subset (D). n = 25, covariate correlation analysis. MONO monocytes, Aβ amyloid-β protein.CC BY · PubMed Central
Fig. 4 Association of monocyte Aβ1-42 uptake with plasma Aβ1-40 levels in CN subjects. Correlations between plasma Aβ1-42 and the uptake of Aβ1-42 by all monocytes (A), by the CD14+CD16− subset (B), by the CD14+CD16+ subset (C) and by the CD14dimCD16− subset (D). n = 25, covariate correlation analysis. MONO monocytes, Aβ amyloid-β protein.
Fig. 4 Association of monocyte Aβ1-42 uptake with plasma Aβ1-40 levels in CN subjects. Correlations between plasma Aβ1-42 and the uptake of Aβ1-42 by all monocytes (A), by the CD14+CD16− subset (B), by the CD14+CD16+ subset (C) and by the CD14dimCD16− subset (D). n = 25, covariate correlation analysis. MONO monocytes, Aβ amyloid-β protein.CC BY · PubMed Central
Fig. 5 Comparison of Aβ1-42 uptake by monocyte subsets between AD patients and CN subjects. Compared with CN controls, AD patients had decreased Aβ1-42 uptake by total monocytes (A), the CD14+CD16− subset (B), the CD14+CD16+ subset (C) and the CD14dimCD16− subset (D). n = 24 for AD; n = 25 for CN, mean ± SEM, Student’s t test, two sided. AD Alzheimer’s disease, CN cognitively normal control, MONO monocytes, Aβ amyloid-β protein.
Fig. 5 Comparison of Aβ1-42 uptake by monocyte subsets between AD patients and CN subjects. Compared with CN controls, AD patients had decreased Aβ1-42 uptake by total monocytes (A), the CD14+CD16− subset (B), the CD14+CD16+ subset (C) and the CD14dimCD16− subset (D). n = 24 for AD; n = 25 for CN, mean ± SEM, Student’s t test, two sided. AD Alzheimer’s disease, CN cognitively normal control, MONO monocytes, Aβ amyloid-β protein.CC BY · PubMed Central
Fig. 6 Detection of Aβ1-42 uptake-related receptors and Aβ-degrading enzymes in the monocytes of AD patients. A Following CD14-positive selection by magnetic activated cell sorting, monocytes were identified by flow cytometry by their forward-side-scatter appearance (n = 21 for AD; n = 18 for CN, mean ± SEM). B–F The expression of TLR2, TREM2, CD36, CD33 and MSR1 was assessed in monocytes, and the expression levels are depicted in representative histograms; grey curves indicate negative control staining (n = 21 for AD; n = 18 for CN, mean ± SEM; Student’s t test, two sided). G The expression level of TLR2 was decreased in AD patients compared with CN subjects (n = 21 for AD; n = 18 for CN, mean ± SEM; Student’s t test, two sided). H–K There was no significant difference between AD patients and CN controls in the expression levels of TREM2, CD36, CD33 and MSR1 (n = 21 for AD; n = 18 for CN, mean ± SEM; Mann–Whitney test or Student’s t test, two sided). I–M There was no significant difference between AD patients and CN controls in the expression levels of Aβ-degrading enzymes, including cathepsin D and cathepsin S (n = 12 for AD; n = 12 for CN, mean ± SEM; Mann–Whitney test or Student’s t test, two sided). AD Alzheimer’s disease, CN cognitively normal control, Aβ amyloid β-protein, TLR2 Toll-like receptor 2, TREM2 triggering receptor expressed on myeloid cells 2, SCARA1 macrophage scavenger receptor 1.
Fig. 6 Detection of Aβ1-42 uptake-related receptors and Aβ-degrading enzymes in the monocytes of AD patients. A Following CD14-positive selection by magnetic activated cell sorting, monocytes were identified by flow cytometry by their forward-side-scatter appearance (n = 21 for AD; n = 18 for CN, mean ± SEM). B–F The expression of TLR2, TREM2, CD36, CD33 and MSR1 was assessed in monocytes, and the expression levels are depicted in representative histograms; grey curves indicate negative control staining (n = 21 for AD; n = 18 for CN, mean ± SEM; Student’s t test, two sided). G The expression level of TLR2 was decreased in AD patients compared with CN subjects (n = 21 for AD; n = 18 for CN, mean ± SEM; Student’s t test, two sided). H–K There was no significant difference between AD patients and CN controls in the expression levels of TREM2, CD36, CD33 and MSR1 (n = 21 for AD; n = 18 for CN, mean ± SEM; Mann–Whitney test or Student’s t test, two sided). I–M There was no significant difference between AD patients and CN controls in the expression levels of Aβ-degrading enzymes, including cathepsin D and cathepsin S (n = 12 for AD; n = 12 for CN, mean ± SEM; Mann–Whitney test or Student’s t test, two sided). AD Alzheimer’s disease, CN cognitively normal control, Aβ amyloid β-protein, TLR2 Toll-like receptor 2, TREM2 triggering receptor expressed on myeloid cells 2, SCARA1 macrophage scavenger receptor 1.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Cited by

See all 89

Metadata

Authors
Chen, S.-H., Tian, D.-Y., Shen, Y.-Y., Cheng, Y., Fan, D.-Y., Sun, H.-L., He, C.-Y., Sun, P.-Y., Bu, X.-L., Zeng, F., Liu, J., Deng, J., Xu, Z.-Q., Chen, Y., & Wang, Y.-J.
Affiliations
Army Medical University (CN)
Corresponding author
  • He, Chen-Yang
  • Chen, Yang
  • Wang, Yan-Jiang
Venue
Translational Psychiatry
Published
2020-12-08
Volume
10
Issue
1
Pages
423-423
ISSN
2158-3188 (ISSN-L)
OpenAlex
W3112519475
Cited by
89
References
42
Citations by year
2026: 9 · 2025: 13 · 2024: 22 · 2023: 16 · 2022: 11 · 2021: 18
FWCI
6.77
Type
journal article
Language
en
Open access
Licence
Locations
  • Translational Psychiatry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China (91749206, 81625007, 31921003)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
amyloid-beta, blood monocytes, Alzheimer's disease, aging, amyloid-beta clearance, phagocytosis, amyloid-beta 42, TLR2, Parkinson's disease, peripheral blood mononuclear cells, treatment options
MeSH terms
Aging, Alzheimer Disease, Humans, Monocytes, Phagocytosis, Amyloid beta-Peptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Amyloid-beta uptake by blood monocytes is reduced with ageing and Alzheimer’s disease. https://app.cochat.ai/papers/10.1038/s41398-020-01113-9
The paper
Chen, S.-H., Tian, D.-Y., Shen, Y.-Y., Cheng, Y., Fan, D.-Y., Sun, H.-L., He, C.-Y., Sun, P.-Y., Bu, X.-L., Zeng, F., Liu, J., Deng, J., Xu, Z.-Q., Chen, Y., & Wang, Y.-J. (2020). Amyloid-beta uptake by blood monocytes is reduced with ageing and Alzheimer’s disease. Translational Psychiatry. https://doi.org/10.1038/s41398-020-01113-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.